A Study of AMDX-2011P in Participants With CAA
Start Date
7/9/2024
Completion Date
12/1/2026
Summary
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).
Detailed Description
This open-label, masked endpoint assessment study will evaluate the safety, tolerability, plasma pharmacokinetics (PK) and biological activity of an intravenous (IV) dose of AMDX-2011P in participants with CAA. Assessments of retinal images will be conducted by central masked assessors. Participants will be admitted to the study site where eye examination and retinal imaging will be conducted before administration of the study drug. AMDX-2011P will be administered through a single IV bolus injection followed by safety assessments, retinal imaging and PK blood collection.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
AMDX-2011P
Conditions
Locations
Associated Retina Consultants
Phoenix, Arizona 85020
United States